Tau phosphorylation and aggregation as a therapeutic target in tauopathies

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 727-740

  Badiola, Nahuai ^a,b   Suárez Calvet, Marc ^a,b   Lleó, Alberto ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Alzheimer; Dementia; Frontotemporal dementia; Immunization; Kinase inhibitors; Tau; Tauopathies

Indexed keywords

1,2,5 THIADIAZOLIDINE 1,1 DIOXIDE DERIVATIVE; 4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; AL 108; AMYLOID; ANTHRAQUINONE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; ARA 014418; ASPARAGINYLALANYLPROLYLVALYLSERYLISOLEUCYLGLUTAMINE; AZD 1080; CHIR 98014; CYANINE DYE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HEAT SHOCK PROTEIN 90 INHIBITOR; LITHIUM CHLORIDE; METHYLENE BLUE; N 744; OCTAPEPTIDE; PACLITAXEL; PHENOTHIAZINE DERIVATIVE; PLACEBO; POLYPHENOL DERIVATIVE; PORPHYRIN DERIVATIVE; PU24FCL; QUINOXALINE; REMBER; SRN 003556; TAU PROTEIN; TIDEGLUSIB; UNCLASSIFIED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; BIOLOGICAL ACTIVITY; BIPOLAR DISORDER; CARBOXY TERMINAL SEQUENCE; CLINICAL FEATURE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CORTICOBASAL DEGENERATION; DRUG BIOAVAILABILITY; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC CORRELATION; GENETIC VARIABILITY; HUMAN; IMMUNOTHERAPY; MICROTUBULE ASSEMBLY; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; MULTIPHOTON MICROSCOPY; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; NIEMANN PICK DISEASE; NONHUMAN; PICK PRESENILE DEMENTIA; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; SCHIZOPHRENIA; TAUOPATHY; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT;

EID: 78649251547     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237403     Document Type: Article

References (225)

1. Lleo, A.; Greenberg, S.M.; Growdon, J.H. Current pharmacotherapyfor Alzheimer's disease. Annu. Rev. Med., 2006, 57, 513-533.
2. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372(9634), 216-223.
3. Lee, V.M.; Goedert, M.; Trojanowski, J.Q. Neurodegenerativetauopathies. Annu. Rev. Neurosci., 2001, 24, 1121-1159.
4. Iqbal, K.; Liu, F.; Gong, C.X.; Alonso Adel, C.; Grundke-Iqbal, I.Mechanisms of tau-induced neurodegeneration. Acta Neuropathol., 2009, 118(1), 53-69.
5. Komori, T. Tau-positive glial inclusions in progressivesupranuclear palsy, corticobasal degeneration and Pick's disease.Brain Pathol., 1999, 9(4), 663-679.
6. Kidd, M. Paired helical filaments in electron microscopy ofAlzheimer's disease. Nature, 1963, 197, 192-193.
7. Hirano, A.; Dembitzer, H.M.; Kurland, L.T.; Zimmerman, H.M.The fine structure of some intraganglionic alterations.Neurofibrillary tangles, granulovacuolar bodies and rod-likestructures as seen in Guam amyotrophic lateral sclerosis andparkinsonism-dementia complex. J. Neuropathol. Exp. Neurol., 1968, 27(2), 167-182.
8. Arriagada, P.V.; Growdon, J.H.; Hedley-Whyte, E.T.; Hyman, B.T. Neurofibrillary tangles but not senile plaques parallel duration andseverity of Alzheimer's disease. Neurology, 1992, 42(3 Pt 1), 631-639.
9. Gomez-Isla, T.; Hollister, R.; West, H.; Mui, S.; Growdon, J.H.; Petersen, R.C.; Parisi, J.E.; Hyman, B.T. Neuronal loss correlateswith but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol., 1997, 41(1), 17-24.
10. Ingelsson, M.; Fukumoto, H.; Newell, K.L.; Growdon, J.H.; Hedley-Whyte, E.T.; Frosch, M.P.; Albert, M.S.; Hyman, B.T.; Irizarry, M.C. Early Abeta accumulation and progressive synapticloss, gliosis, and tangle formation in AD brain. Neurology, 2004, 62(6), 925-931.
11. Serrano-Pozo, A.; William, C.M.; Ferrer, I.; Uro-Coste, E.; Delisle, M.B.; Maurage, C.A.; Hock, C.; Nitsch, R.M.; Masliah, E.; Growdon, J.; Frosch, M.P.; Hyman, B. Beneficial effect of humananti-Ab active immunization on neurite morphology and taupathology. Brain, 2010, 133(Pt 5), 1312-1327.
12. Ludolph, A.C.; Kassubek, J.; Landwehrmeyer, B.G.; Mandelkow, E.; Mandelkow, E.M.; Burn, D.J.; Caparros-Lefebvre, D.; Frey, K.A.; de Yebenes, J.G.; Gasser, T.; Heutink, P.; Hoglinger, G.; Jamrozik, Z.; Jellinger, K.A.; Kazantsev, A.; Kretzschmar, H.; Lang, A.E.; Litvan, I.; Lucas, J.J.; McGeer, P.L.; Melquist, S.; Oertel, W.; Otto, M.; Paviour, D.; Reum, T.; Saint-Raymond, A.; Steele, J.C.; Tolnay, M.; Tumani, H.; van Swieten, J.C.; Vanier, M.T.; Vonsattel, J.P.; Wagner, S.; Wszolek, Z.K. Tauopathies withparkinsonism: clinical spectrum, neuropathologic basis, biologicalmarkers, and treatment options. Eur. J. Neurol., 2009, 16(3), 297-309.
13. Steele, J.C.; Richardson, J.C.; Olszewski, J. Progressivesupranuclear palsy. A heterogeneous degeneration involving thebrain stem, basal ganglia and cerebellum with vertical gaze andpseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol., 1964, 10, 333-359.
14. Williams, D.R.; Lees, A.J. Progressive supranuclear palsy:clinicopathological concepts and diagnostic challenges. LancetNeurol., 2009, 8(3), 270-279.
15. Cordato, N.J.; Halliday, G.M.; McCann, H.; Davies, L.; Williamson, P.; Fulham, M.; Morris, J.G. Corticobasal syndromewith tau pathology. Mov. Disord., 2001, 16(4), 656-667.
16. Lleo, A.; Rey, M.J.; Castellvi, M.; Ferrer, I.; Blesa, R. Asymmetricmyoclonic parietal syndrome in a patient with Alzheimer's diseasemimicking corticobasal degeneration. Neurologia, 2002, 17(4), 223-226.
17. Hutton, M.; Lendon, C.L.; Rizzu, P.; Baker, M.; Froelich, S.; Houlden, H.; Pickering-Brown, S.; Chakraverty, S.; Isaacs, A.; Grover, A.; Hackett, J.; Adamson, J.; Lincoln, S.; Dickson, D.; Davies, P.; Petersen, R.C.; Stevens, M.; de Graaff, E.; Wauters, E.; van Baren, J.; Hillebrand, M.; Joosse, M.; Kwon, J.M.; Nowotny, P.; Che, L.K.; Norton, J.; Morris, J.C.; Reed, L.A.; Trojanowski, J.; Basun, H.; Lannfelt, L.; Neystat, M.; Fahn, S.; Dark, F.; Tannenberg, T.; Dodd, P.R.; Hayward, N.; Kwok, J.B.; Schofield, P.R.; Andreadis, A.; Snowden, J.; Craufurd, D.; Neary, D.; Owen, F.; Oostra, B.A.; Hardy, J.; Goate, A.; van Swieten, J.; Mann, D.; Lynch, T.; Heutink, P. Association of missense and 5'-splice-sitemutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393(6686), 702-705.
18. Poorkaj, P.; Bird, T.D.; Wijsman, E.; Nemens, E.; Garruto, R.M.; Anderson, L.; Andreadis, A.; Wiederholt, W.C.; Raskind, M.; Schellenberg, G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol., 1998, 43(6), 815-825.
19. Spillantini, M.G.; Murrell, J.R.; Goedert, M.; Farlow, M.R.; Klug, A.; Ghetti, B. Mutation in the tau gene in familial multiple systemtauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA, 1998, 95(13), 7737-7741.
20. Bugiani, O.; Murrell, J.R.; Giaccone, G.; Hasegawa, M.; Ghigo, G.; Tabaton, M.; Morbin, M.; Primavera, A.; Carella, F.; Solaro, C.; Grisoli, M.; Savoiardo, M.; Spillantini, M.G.; Tagliavini, F.; Goedert, M.; Ghetti, B. Frontotemporal dementia and corticobasaldegeneration in a family with a P301S mutation in tau. J.Neuropathol. Exp. Neurol., 1999, 58(6), 667-677.
21. Casseron, W.; Azulay, J.P.; Guedj, E.; Gastaut, J.L.; Pouget, J. Familial autosomal dominant cortico-basal degeneration with theP301S mutation in the tau gene: an example of phenotypevariability. J. Neurol., 2005, 252(12), 1546-1548.
22. Hodges, J.R.; Davies, R.R.; Xuereb, J.H.; Casey, B.; Broe, M.; Bak, T.H.; Kril, J.J.; Halliday, G.M. Clinicopathological correlatesin frontotemporal dementia. Ann. Neurol., 2004, 56(3), 399-406.
23. Josephs, K.A.; Petersen, R.C.; Knopman, D.S.; Boeve, B.F.; Whitwell, J.L.; Duffy, J.R.; Parisi, J.E.; Dickson, D.W. linicopathologic analysis of frontotemporal and corticobasaldegenerations and PSP. Neurology, 2006, 66(1), 41-48.
24. Kertesz, A.; McMonagle, P.; Blair, M.; Davidson, W.; Munoz, D.G. The evolution and pathology of frontotemporal dementia.Brain, 2005, 128(Pt 9), 1996-2005.
25. Josephs, K.A.; Duffy, J.R.; Strand, E.A.; Whitwell, J.L.; Layton, K.F.; Parisi, J.E.; Hauser, M.F.; Witte, R.J.; Boeve, B.F.; Knopman, D.S.; Dickson, D.W.; Jack, C.R., Jr.; Petersen, R.C. Clinicopathological and imaging correlates of progressive aphasiaand apraxia of speech. Brain, 2006, 129(Pt 6), 1385-1398.
26. Josephs, K.A.; Whitwell, J.L.; Dickson, D.W.; Boeve, B.F.; Knopman, D.S.; Petersen, R.C.; Parisi, J.E.; Jack, C.R., Jr. Voxelbasedmorphometry in autopsy proven PSP and CBD. Neurobiol.Aging, 2008, 29(2), 280-289.
27. Whitwell, J.L.; Josephs, K.A.; Rossor, M.N.; Stevens, J.M.; Revesz, T.; Holton, J.L.; Al-Sarraj, S.; Godbolt, A.K.; Fox, N.C.; Warren, J.D. Magnetic resonance imaging signatures of tissuepathology in frontotemporal dementia. Arch. Neurol., 2005, 62(9), 1402-1408.
28. Casals, J.; Elizan, T.S.; Yahr, M.D. Postencephalitic parkinsonism--a review. J. Neural Transm., 1998, 105(6-7), 645-676.
29. McKee, A.C.; Cantu, R.C.; Nowinski, C.J.; Hedley-Whyte, E.T.; Gavett, B.E.; Budson, A.E.; Santini, V.E.; Lee, H.S.; Kubilus, C.A.; Stern, R.A. Chronic traumatic encephalopathy in athletes:progressive tauopathy after repetitive head injury. J. Neuropathol.Exp. Neurol., 2009, 68(7), 709-735.
30. Andreadis, A.; Brown, W.M.; Kosik, K.S. Structure and novelexons of the human tau gene. Biochemistry, 1992, 31(43), 10626-10633.
31. Goedert, M.; Spillantini, M.G.; Potier, M.C.; Ulrich, J.; Crowther, A. Cloning and sequencing of the cDNA encoding an isoform ofmicrotubule-associated protein tau containing four tandem repeats:differential expression of tau protein mRNAs in human brain.EMBO J., 1989, 8(2), 393-399.
32. Goedert, M.; Wischik, C.M.; Crowther, R.A.; Walker, J.E.; Klug, A. Cloning and sequencing of the cDNA encoding a core protein ofthe paired helical filament of Alzheimer disease: identification asthe microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA, 1988, 85(11), 4051-4055.
33. Goedert, M.; Spillantini, M.G.; Jakes, R.; Rutherford, D.; Crowther, R.A. Multiple isoforms of human microtubuleassociatedprotein tau: sequences and localization in neurofibrillarytangles of Alzheimer's disease. Neuron, 1989, 3(4), 519-526.
34. Himmler, A.; Drechsel, D.; Kirschner, M.W.; Martin, D.W., Jr. Tauconsists of a set of proteins with repeated C-terminal microtubulebindingdomains and variable N-terminal domains. Mol. Cell Biol., 1989, 9(4), 1381-1388.
35. Lee, G.; Neve, R.L.; Kosik, K.S. The microtubule binding domainof tau protein. Neuron, 1989, 2(6), 1615-1624.
36. Delacourte, A.; David, J.P.; Sergeant, N.; Buee, L.; Wattez, A.; Vermersch, P.; Ghozali, F.; Fallet-Bianco, C.; Pasquier, F.; Lebert, F.; Petit, H.; Di Menza, C. The biochemical pathway ofneurofibrillary degeneration in aging and Alzheimer's disease.Neurology, 1999, 52(6), 1158-1165.
37. Alzheimer Disease & Frontotemporal Dementia MutationDatabase. http://www.molgen.ua.ac.be/ADMutations (accessedNov 23, 2009).
38. Pickering-Brown, S.; Hutton, M. The genetics of frontotemporaldementia. Handb. Clin. Neurol., 2008, 89, 383-392.
39. Dayanandan, R.; Van Slegtenhorst, M.; Mack, T.G.; Ko, L.; Yen, S.H.; Leroy, K.; Brion, J.P.; Anderton, B.H.; Hutton, M.; Lovestone, S. Mutations in tau reduce its microtubule bindingproperties in intact cells and affect its phosphorylation. FEBS Lett., 1999, 446(2-3), 228-232.
40. Hasegawa, M.; Smith, M.J.; Goedert, M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubuleassembly. FEBS Lett., 1998, 437(3), 207-210.
41. Hong, M.; Zhukareva, V.; Vogelsberg-Ragaglia, V.; Wszolek, Z.; Reed, L.; Miller, B.I.; Geschwind, D.H.; Bird, T.D.; McKeel, D.; Goate, A.; Morris, J.C.; Wilhelmsen, K.C.; Schellenberg, G.D.; Trojanowski, J.Q.; Lee, V.M. Mutation-specific functionalimpairments in distinct tau isoforms of hereditary FTDP-17.Science, 1998, 282(5395), 1914-1917.
42. Pickering-Brown, S.M.; Baker, M.; Nonaka, T.; Ikeda, K.; Sharma, S.; Mackenzie, J.; Simpson, S.A.; Moore, J.W.; Snowden, J.S.; deSilva, R.; Revesz, T.; Hasegawa, M.; Hutton, M.; Mann, D.M. Frontotemporal dementia with Pick-type histology associated withQ336R mutation in the tau gene. Brain, 2004, 127(Pt 6), 1415-1426.
43. Nacharaju, P.; Lewis, J.; Easson, C.; Yen, S.; Hackett, J.; Hutton, M.; Yen, S.H. Accelerated filament formation from tau proteinwith specific FTDP-17 missense mutations. FEBS Lett., 1999, 447(2-3), 195-199.
44. Rizzini, C.; Goedert, M.; Hodges, J.R.; Smith, M.J.; Jakes, R.; Hills, R.; Xuereb, J.H.; Crowther, R.A.; Spillantini, M.G. Tau genemutation K257T causes a tauopathy similar to Pick's disease. J.Neuropathol. Exp. Neurol., 2000, 59(11), 990-1001.
45. Alonso, A.D.; Grundke-Iqbal, I.; Barra, H.S.; Iqbal, K. Abnormalphosphorylation of tau and the mechanism of Alzheimerneurofibrillary degeneration: sequestration of microtubuleassociatedproteins 1 and 2 and the disassembly of microtubules bythe abnormal tau. Proc. Natl. Acad. Sci. USA, 1997, 94(1), 298-303.
46. Bhaskar, K.; Yen, S.H.; Lee, G. Disease-related modifications intau affect the interaction between Fyn and Tau. J. Biol. Chem., 2005, 280(42), 35119-35125.
47. Rademakers, R.; Cruts, M.; van Broeckhoven, C. The role of tau(MAPT) in frontotemporal dementia and related tauopathies. Hum.Mutat., 2004, 24(4), 277-295.
48. Stanford, P.M.; Shepherd, C.E.; Halliday, G.M.; Brooks, W.S.; Schofield, P.W.; Brodaty, H.; Martins, R.N.; Kwok, J.B.; Schofield, P.R. Mutations in the tau gene that cause an increase inthree repeat tau and frontotemporal dementia. Brain, 2003, 126(Pt4), 814-826.
49. Baker, M.; Litvan, I.; Houlden, H.; Adamson, J.; Dickson, D.; Perez-Tur, J.; Hardy, J.; Lynch, T.; Bigio, E.; Hutton, M. Association of an extended haplotype in the tau gene withprogressive supranuclear palsy. Hum. Mol. Genet., 1999, 8(4), 711-715.
50. Bennett, P.; Bonifati, V.; Bonuccelli, U.; Colosimo, C.; De Mari, M.; Fabbrini, G.; Marconi, R.; Meco, G.; Nicholl, D.J.; Stocchi, F.; Vanacore, N.; Vieregge, P.; Williams, A.C. Direct genetic evidencefor involvement of tau in progressive supranuclear palsy. EuropeanStudy Group on Atypical Parkinsonism Consortium. Neurology, 1998, 51(4), 982-985.
51. Conrad, C.; Andreadis, A.; Trojanowski, J.Q.; Dickson, D.W.; ang, D.; Chen, X.; Wiederholt, W.; Hansen, L.; Masliah, E.; Thal, L.J.; Katzman, R.; Xia, Y.; Saitoh, T. Genetic evidence for theinvolvement of tau in progressive supranuclear palsy. Ann. Neurol., 1997, 41(2), 277-281.
52. Higgins, J.J.; Golbe, L.I.; De Biase, A.; Jankovic, J.; Factor, S.A.; Adler, R.L. An extended 5'-tau susceptibility haplotype inprogressive supranuclear palsy. Neurology, 2000, 55(9), 1364-1367.
53. Morris, H.R.; Janssen, J.C.; Bandmann, O.; Daniel, S.E.; Rossor, M.N.; Lees, A.J.; Wood, N.W. The tau gene A0 polymorphism inprogressive supranuclear palsy and related neurodegenerativediseases. J. Neurol. Neurosurg. Psychiatry, 1999, 66(5), 665-667.
54. Oliva, R.; Tolosa, E.; Ezquerra, M.; Molinuevo, J.L.; Valldeoriola, F.; Burguera, J.; Calopa, M.; Villa, M.; Ballesta, F. Significantchanges in the tau A0 and A3 alleles in progressive supranuclearpalsy and improved genotyping by silver detection. Arch. Neurol., 1998, 55(8), 1122-1124.
55. Di Maria, E.; Tabaton, M.; Vigo, T.; Abbruzzese, G.; Bellone, E.; Donati, C.; Frasson, E.; Marchese, R.; Montagna, P.; Munoz, D.G.; Pramstaller, P.P.; Zanusso, G.; Ajmar, F.; Mandich, P. Corticobasaldegeneration shares a common genetic background withprogressive supranuclear palsy. Ann. Neurol., 2000, 47(3), 374-377.
56. Houlden, H.; Baker, M.; Morris, H.R.; MacDonald, N.; Pickering-Brown, S.; Adamson, J.; Lees, A.J.; Rossor, M.N.; Quinn, N.P.; Kertesz, A.; Khan, M.N.; Hardy, J.; Lantos, P.L.; St George-Hyslop, P.; Munoz, D.G.; Mann, D.; Lang, A.E.; Bergeron, C.; Bigio, E.H.; Litvan, I.; Bhatia, K.P.; Dickson, D.; Wood, N.W.; Hutton, M. Corticobasal degeneration and progressive supranuclearpalsy share a common tau haplotype. Neurology, 2001, 56(12), 1702-1706.
57. Myers, A.J.; Kaleem, M.; Marlowe, L.; Pittman, A.M.; Lees, A.J.; Fung, H.C.; Duckworth, J.; Leung, D.; Gibson, A.; Morris, C.M.; de Silva, R.; Hardy, J. The H1c haplotype at the MAPT locus isassociated with Alzheimer's disease. Hum. Mol. Genet., 2005, 14(16), 2399-2404.
58. Healy, D.G.; Abou-Sleiman, P.M.; Lees, A.J.; Casas, J.P.; Quinn, N.; Bhatia, K.; Hingorani, A.D.; Wood, N.W. Tau gene andParkinson's disease: a case-control study and meta-analysis. J.Neurol. Neurosurg. Psychiatry, 2004, 75(7), 962-965.
59. Simon-Sanchez, J.; Schulte, C.; Bras, J.M.; Sharma, M.; Gibbs, J.R.; Berg, D.; Paisan-Ruiz, C.; Lichtner, P.; Scholz, S.W.; Hernandez, D.G.; Kruger, R.; Federoff, M.; Klein, C.; Goate, A.; Perlmutter, J.; Bonin, M.; Nalls, M.A.; Illig, T.; Gieger, C.; Houlden, H.; Steffens, M.; Okun, M.S.; Racette, B.A.; Cookson, M.R.; Foote, K.D.; Fernandez, H.H.; Traynor, B.J.; Schreiber, S.; Arepalli, S.; Zonozi, R.; Gwinn, K.; van der Brug, M.; Lopez, G.; Chanock, S.J.; Schatzkin, A.; Park, Y.; Hollenbeck, A.; Gao, J.; Huang, X.; Wood, N.W.; Lorenz, D.; Deuschl, G.; Chen, H.; Riess, O.; Hardy, J.A.; Singleton, A.B.; Gasser, T. Genome-wideassociation study reveals genetic risk underlying Parkinson'sdisease. Nat. Genet., 2009, 41(12), 1308-1312.
60. Ghidoni, R.; Signorini, S.; Barbiero, L.; Sina, E.; Cominelli, P.; Villa, A.; Benussi, L.; Binetti, G. The H2 MAPT haplotype isassociated with familial frontotemporal dementia. Neurobiol. Dis., 2006, 22(2), 357-362.
61. Ingelson, M.; Fabre, S.F.; Lilius, L.; Andersen, C.; Viitanen, M.; Almkvist, O.; Wahlund, L.O.; Lannfelt, L. Increased risk forfrontotemporal dementia through interaction between taupolymorphisms and apolipoprotein E epsilon4. Neuroreport, 2001, 12(5), 905-909.
62. Johansson, A.; Zetterberg, H.; Hakansson, A.; Nissbrandt, H.; Blennow, K. TAU haplotype and the Saitohin Q7R genepolymorphism do not influence CSF Tau in Alzheimer's diseaseand are not associated with frontotemporal dementia or Parkinson'sdisease. Neurodegener. Dis., 2005, 2(1), 28-35.
63. Laws, S.M.; Friedrich, P.; Diehl-Schmid, J.; Muller, J.; Ibach, B.; Bauml, J.; Eisele, T.; Forstl, H.; Kurz, A.; Riemenschneider, M. Genetic analysis of MAPT haplotype diversity in frontotemporaldementia. Neurobiol. Aging, 2008, 29(8), 1276-1278.
64. Cleveland, D.W.; Hwo, S.Y.; Kirschner, M.W. Purification of tau, a microtubule-associated protein that induces assembly ofmicrotubules from purified tubulin. J. Mol. Biol., 1977, 116(2), 207-225.
65. Weingarten, M.D.; Lockwood, A.H.; Hwo, S.Y.; Kirschner, M.W.A protein factor essential for microtubule assembly. Proc. Natl.Acad. Sci. USA, 1975, 72(5), 1858-1862.
66. Binder, L.I.; Frankfurter, A.; Rebhun, L.I. The distribution of tau inthe mammalian central nervous system. J. Cell. Biol., 1985, 101(4), 1371-1378.
67. Baas, P.W.; Qiang, L. Neuronal microtubules: when the MAP isthe roadblock. Trends Cell Biol., 2005, 15(4), 183-187.
68. Dixit, R.; Ross, J.L.; Goldman, Y.E.; Holzbaur, E.L. Differentialregulation of dynein and kinesin motor proteins by tau. Science, 2008, 319(5866), 1086-1089.
69. Mandelkow, E.M.; Stamer, K.; Vogel, R.; Thies, E.; Mandelkow, E. Clogging of axons by tau, inhibition of axonal traffic andstarvation of synapses. Neurobiol. Aging, 2003, 24(8), 1079-1085.
70. Thies, E.; Mandelkow, E.M. Missorting of tau in neurons causesdegeneration of synapses that can be rescued by the kinaseMARK2/Par-1. J. Neurosci., 2007, 27(11), 2896-2907.
71. Yuan, A.; Kumar, A.; Peterhoff, C.; Duff, K.; Nixon, R.A. Axonaltransport rates in vivo are unaffected by tau deletion oroverexpression in mice. J. Neurosci., 2008, 28(7), 1682-1687.
72. Selden, S.C.; Pollard, T.D. Phosphorylation of microtubuleassociatedproteins regulates their interaction with actin filaments.J. Biol. Chem., 1983, 258(11), 7064-7071.
73. Henriquez, J.P.; Cross, D.; Vial, C.; Maccioni, R.B. Subpopulationsof tau interact with microtubules and actin filaments in various celltypes. Cell Biochem. Funct., 1995, 13(4), 239-250.
74. Yamauchi, P.S.; Purich, D.L. Microtubule-associated proteininteractions with actin filaments: evidence for differential behaviorof neuronal MAP-2 and tau in the presence of phosphatidylinositol.Biochem. Biophys. Res. Commun., 1993, 190(3), 710-715.
75. Farias, G.A.; Munoz, J.P.; Garrido, J.; Maccioni, R.B. Tubulin, actin, and tau protein interactions and the study of theirmacromolecular assemblies. J. Cell Biochem., 2002, 85(2), 315-324.
76. Fulga, T.A.; Elson-Schwab, I.; Khurana, V.; Steinhilb, M.L.; Spires, T.L.; Hyman, B.T.; Feany, M.B. Abnormal bundling andaccumulation of F-actin mediates tau-induced neuronaldegeneration in vivo. Nat. Cell Biol., 2007, 9(2), 139-148.
77. Amos, L.A. Microtubule structure and its stabilisation. Org.Biomol. Chem., 2004, 2(15), 2153-2160.
78. Schweers, O.; Schonbrunn-Hanebeck, E.; Marx, A.; Mandelkow, E. Structural studies of tau protein and Alzheimer paired helicalfilaments show no evidence for beta-structure. J. Biol. Chem., 1994, 269(39), 24290-24297.
79. Bellucci, A.; Rosi, M.C.; Grossi, C.; Fiorentini, A.; Luccarini, I.; Casamenti, F. Abnormal processing of tau in the brain of agedTgCRND8 mice. Neurobiol. Dis., 2007, 27(3), 328-338.
80. Gong, C.X.; Liu, F.; Grundke-Iqbal, I.; Iqbal, K. Post-translationalmodifications of tau protein in Alzheimer's disease. J. NeuralTransm., 2005, 112(6), 813-838.
81. Pevalova, M.; Filipcik, P.; Novak, M.; Avila, J.; Iqbal, K. Posttranslationalmodifications of tau protein. Bratisl. Lek. Listy, 2006, 107(9-10), 346-353.
82. Stoothoff, W.H.; Johnson, G.V. Tau phosphorylation: physiologicaland pathological consequences. Biochim. Biophys. Acta, 2005, 1739(2-3), 280-297.
83. Mazanetz, M.P.; Fischer, P.M. Untangling tau hyperphosphorylation indrug design for neurodegenerative diseases. Nat. Rev. DrugDiscov., 2007, 6(6), 464-479.
84. Hanger, D.P.; Byers, H.L.; Wray, S.; Leung, K.Y.; Saxton, M.J.; Seereeram, A.; Reynolds, C.H.; Ward, M.A.; Anderton, B.H. Novelphosphorylation sites in tau from Alzheimer brain support a role forcasein kinase 1 in disease pathogenesis. J. Biol. Chem., 2007, 282(32), 23645-23654.
85. Sergeant, N.; Bretteville, A.; Hamdane, M.; Caillet-Boudin, M.L.; Grognet, P.; Bombois, S.; Blum, D.; Delacourte, A.; Pasquier, F.; Vanmechelen, E.; Schraen-Maschke, S.; Buee, L. Biochemistry ofTau in Alzheimer's disease and related neurological disorders.Expert Rev. Proteomics, 2008, 5(2), 207-224.
86. Sengupta, A.; Kabat, J.; Novak, M.; Wu, Q.; Grundke-Iqbal, I.; Iqbal, K. Phosphorylation of tau at both Thr 231 and Ser 262 isrequired for maximal inhibition of its binding to microtubules.Arch. Biochem. Biophys., 1998, 357(2), 299-309.
87. Alonso Adel, C.; Mederlyova, A.; Novak, M.; Grundke-Iqbal, I.; Iqbal, K. Promotion of hyperphosphorylation by frontotemporaldementia tau mutations. J. Biol. Chem., 2004, 279(33), 34873-34881.
88. Abraha, A.; Ghoshal, N.; Gamblin, T.C.; Cryns, V.; Berry, R.W.; Kuret, J.; Binder, L.I. C-terminal inhibition of tau assembly in vitroand in Alzheimer's disease. J. Cell Sci., 2000, 113(Pt 21), 3737-3745.
89. Haase, C.; Stieler, J.T.; Arendt, T.; Holzer, M. Pseudophosphorylationof tau protein alters its ability for self-aggregation. J. Neurochem., 2004, 88(6), 1509-1520.
90. Avila, J. Tau phosphorylation and aggregation in Alzheimer'sdisease pathology. FEBS Lett., 2006, 580(12), 2922-2927.
91. Wang, J.Z.; Grundke-Iqbal, I.; Iqbal, K. Glycosylation ofmicrotubule-associated protein tau: an abnormal posttranslationalmodification in Alzheimer's disease. Nat. Med., 1996, 2(8), 871-875.
92. Arnold, C.S.; Johnson, G.V.; Cole, R.N.; Dong, D.L.; Lee, M.; Hart, G.W. The microtubule-associated protein tau is extensivelymodified with O-linked N-acetylglucosamine. J. Biol. Chem., 1996, 271(46), 28741-28744.
93. Li, X.; Lu, F.; Wang, J.Z.; Gong, C.X. Concurrent alterations of OGlcNAcylationand phosphorylation of tau in mouse brains duringfasting. Eur. J. Neurosci., 2006, 23(8), 2078-2086.
94. Yuzwa, S.A.; Vocadlo, D.J. O-Glcnac modification and thetauopathies: insights from chemical biology. Curr. Alzheimer Res., 2009, 6(5), 451-454.
95. Gamblin, T.C.; Chen, F.; Zambrano, A.; Abraha, A.; Lagalwar, S.; Guillozet, A.L.; Lu, M.; Fu, Y.; Garcia-Sierra, F.; LaPointe, N.; Miller, R.; Berry, R.W.; Binder, L.I.; Cryns, V.L. Caspase cleavageof tau: linking amyloid and neurofibrillary tangles in Alzheimer'sdisease. Proc. Natl. Acad. Sci. USA, 2003, 100(17), 10032-10037.
96. Park, S.-Y.; Ferreira, A. The generation of a 17 kDa neurotoxicfragment: an alternative mechanism by which tau mediates {beta}-amyloid-induced neurodegeneration. J. Neurosci., 2005, 25(22), 5365-5375.
97. Forman, M.S.; Trojanowski, J.Q.; Lee, V.M. Neurodegenerativediseases: a decade of discoveries paves the way for therapeuticbreakthroughs. Nat. Med., 2004, 10(10), 1055-1063.
98. Hyman, B.T.; Augustinack, J.C.; Ingelsson, M. Transcriptional andconformational changes of the tau molecule in Alzheimer's disease.Biochim. Biophys. Acta, 2005, 1739(2-3), 150-157.
99. Khlistunova, I.; Biernat, J.; Wang, Y.; Pickhardt, M.; von Bergen, M.; Gazova, Z.; Mandelkow, E.; Mandelkow, E.M. Inducibleexpression of Tau repeat domain in cell models of tauopathy:aggregation is toxic to cells but can be reversed by inhibitor drugs.J. Biol. Chem., 2006, 281(2), 1205-1214.
100. Lee, V.M.Y.; Kenyon, T.K.; Trojanowski, J.Q. Transgenic animalmodels of tauopathies. Biochimica et Biophysica Acta (BBA) Mol.Basis Dis., 2005, 1739(2-3), 251-259.
101. Wittmann, C.W.; Wszolek, M.F.; Shulman, J.M.; Salvaterra, P.M.; Lewis, J.; Hutton, M.; Feany, M.B. Tauopathy in Drosophila:neurodegeneration without neurofibrillary tangles. Science, 2001, 293(5530), 711-714.
102. Santacruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.; DeTure, M.; Ramsden, M.; McGowan, E.; Forster, C.; Yue, M.; Orne, J.; Janus, C.; Mariash, A.; Kuskowski, M.; Hyman, B.; Hutton, M.; Ashe, K.H. Tausuppression in a neurodegenerative mouse model improvesmemory function. Science, 2005, 309(5733), 476-481.
103. Spires-Jones, T.L.; de Calignon, A.; Matsui, T.; Zehr, C.; Pitstick, R.; Wu, H.Y.; Osetek, J.D.; Jones, P.B.; Bacskai, B.J.; Feany, M.B.; Carlson, G.A.; Ashe, K.H.; Lewis, J.; Hyman, B.T. In vivoimaging reveals dissociation between caspase activation and acuteneuronal death in tangle-bearing neurons. J. Neurosci., 2008, 28(4), 862-867.
104. Spires-Jones, T.L.; Stoothoff, W.H.; de Calignon, A.; Jones, P.B.; Hyman, B.T. Tau pathophysiology in neurodegeneration: a tangledissue. Trends Neurosci., 2009, 32(3), 150-159.
105. Churcher, I. Tau therapeutic strategies for the treatment ofAlzheimer's disease. Curr. Top Med. Chem., 2006, 6(6), 579-595.
106. Goedert, M.; Hasegawa, M.; Jakes, R.; Lawler, S.; Cuenda, A.; Cohen, P. Phosphorylation of microtubule-associated protein tau bystress-activated protein kinases. FEBS Lett., 1997, 409(1), 57-62.
107. Correas, I.; Diaz-Nido, J.; Avila, J. Microtubule-associated proteintau is phosphorylated by protein kinase C on its tubulin bindingdomain. J. Biol. Chem., 1992, 267(22), 15721-15728.
108. Baudier, J.; Lee, S.H.; Cole, R.D. Separation of the differentmicrotubule-associated tau protein species from bovine brain andtheir mode II phosphorylation by Ca2+/phospholipid-dependentprotein kinase C. J. Biol. Chem., 1987, 262(36), 17584-17590.
109. Drewes, G.; Lichtenberg-Kraag, B.; Doring, F.; Mandelkow, E.M.; Biernat, J.; Goris, J.; Doree, M.; Mandelkow, E. Mitogen activatedprotein (MAP) kinase transforms tau protein into an Alzheimer-likestate. EMBO J., 1992, 11(6), 2131-2138.
110. Hanger, D.P.; Hughes, K.; Woodgett, J.R.; Brion, J.P.; Anderton, B.H. Glycogen synthase kinase-3 induces Alzheimer's disease-likephosphorylation of tau: generation of paired helical filamentepitopes and neuronal localisation of the kinase. Neurosci. Lett., 1992, 147(1), 58-62.
111. Scott, C.W.; Spreen, R.C.; Herman, J.L.; Chow, F.P.; Davison, M.D.; Young, J.; Caputo, C.B. Phosphorylation of recombinant tauby cAMP-dependent protein kinase. Identification ofphosphorylation sites and effect on microtubule assembly. J. Biol.Chem., 1993, 268(2), 1166-1173.
112. Morishima-Kawashima, M.; Hasegawa, M.; Takio, K.; Suzuki, M.; Yoshida, H.; Titani, K.; Ihara, Y. Proline-directed and non-prolinedirectedphosphorylation of PHF-tau. J. Biol. Chem., 1995, 270(2), 823-829.
113. Drewes, G.; Mandelkow, E.M.; Baumann, K.; Goris, J.; Merlevede, W.; Mandelkow, E. Dephosphorylation of tau protein andAlzheimer paired helical filaments by calcineurin and phosphatase-2A. FEBS Lett., 1993, 336(3), 425-432.
114. Liu, F.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X. Contributions ofprotein phosphatases PP1, PP2A, PP2B and PP5 to the regulationof tau phosphorylation. Eur. J. Neurosci., 2005, 22(8), 1942-1950.
115. Tian, Q.; Wang, J. Role of serine/threonine protein phosphatase inAlzheimer's disease. Neurosignals, 2002, 11(5), 262-269.
116. Gong, C.X.; Shaikh, S.; Wang, J.Z.; Zaidi, T.; Grundke-Iqbal, I.; Iqbal, K. Phosphatase activity toward abnormally phosphorylatedtau: decrease in Alzheimer disease brain. J. Neurochem., 1995, 65(2), 732-738.
117. Gong, C.X.; Singh, T.J.; Grundke-Iqbal, I.; Iqbal, K. Phosphoprotein phosphatase activities in Alzheimer disease brain.J. Neurochem., 1993, 61(3), 921-927.
118. Gamblin, T.C.; Berry, R.W.; Binder, L.I. Tau polymerization: roleof the amino terminus. Biochemistry, 2003, 42(7), 2252-2257.
119. Perez, M.; Arrasate, M.; Montejo De Garcini, E.; Munoz, V.; Avila, J. In vitro assembly of tau protein: mapping the regionsinvolved in filament formation. Biochemistry, 2001, 40(20), 5983-5991.
120. Chun, W.; Johnson, G.V. Activation of glycogen synthase kinase3beta promotes the intermolecular association of tau. The use offluorescence resonance energy transfer microscopy. J. Biol. Chem., 2007, 282(32), 23410-23417.
121. Rohn, T.T.; Rissman, R.A.; Davis, M.C.; Kim, Y.E.; Cotman, C.W.; Head, E. Caspase-9 activation and caspase cleavage of tau inthe Alzheimer's disease brain. Neurobiol. Dis., 2002, 11(2), 341-354.
122. Rohn, T.T.; Head, E.; Su, J.H.; Anderson, A.J.; Bahr, B.A.; Cotman, C.W.; Cribbs, D.H. Correlation between caspaseactivation and neurofibrillary tangle formation in Alzheimer'sdisease. Am. J. Pathol., 2001, 158(1), 189-198.
123. Matsui, T.; Ramasamy, K.; Ingelsson, M.; Fukumoto, H.; Conrad, C.; Frosch, M.P.; Irizarry, M.C.; Yuan, J.; Hyman, B.T. Coordinated expression of caspase 8, 3 and 7 mRNA in temporalcortex of Alzheimer disease: relationship to formic acid extractableabeta42 levels. J. Neuropathol. Exp. Neurol., 2006, 65(5), 508-515.
124. Spittaels, K.; Van den Haute, C.; Van Dorpe, J.; Bruynseels, K.; Vandezande, K.; Laenen, I.; Geerts, H.; Mercken, M.; Sciot, R.; Van Lommel, A.; Loos, R.; Van Leuven, F. Prominent axonopathyin the brain and spinal cord of transgenic mice overexpressing fourrepeathuman tau protein. Am. J. Pathol., 1999, 155(6), 2153-2165.
125. Ishihara, T.; Hong, M.; Zhang, B.; Nakagawa, Y.; Lee, M.K.; Trojanowski, J.Q.; Lee, V.M. Age-dependent emergence andprogression of a tauopathy in transgenic mice overexpressing theshortest human tau isoform. Neuron, 1999, 24(3), 751-762.
126. Matsuoka, Y.; Jouroukhin, Y.; Gray, A.J.; Ma, L.; Hirata-Fukae, C.; Li, H.F.; Feng, L.; Lecanu, L.; Walker, B.R.; Planel, E.; Arancio, O.; Gozes, I.; Aisen, P.S. A neuronal microtubuleinteractingagent, NAPVSIPQ, reduces tau pathology and enhancescognitive function in a mouse model of Alzheimer's disease. J.Pharmacol. Exp. Ther., 2008, 325(1), 146-153.
127. Shiryaev, N.; Jouroukhin, Y.; Giladi, E.; Polyzoidou, E.; Grigoriadis, N.C.; Rosenmann, H.; Gozes, I. NAP protects memory, increasessoluble tau and reduces tau hyperphosphorylation in a tauopathy model.Neurobiol. Dis., 2009, 34(2), 381-388.
128. Zhang, B.; Maiti, A.; Shively, S.; Lakhani, F.; McDonald-Jones, G.; Bruce, J.; Lee, E.B.; Xie, S.X.; Joyce, S.; Li, C.; Toleikis, P.M.; Lee, V.M.; Trojanowski, J.Q. Microtubule-binding drugs offset tausequestration by stabilizing microtubules and reversing fast axonaltransport deficits in a tauopathy model. Proc. Natl. Acad. Sci. USA, 2005, 102(1), 227-231.
129. Wang, J.Z.; Wu, Q.; Smith, A.; Grundke-Iqbal, I.; Iqbal, K. Tau isphosphorylated by GSK-3 at several sites found in Alzheimerdisease and its biological activity markedly inhibited only after it isprephosphorylated by A-kinase. FEBS Lett., 1998, 436(1), 28-34.
130. Anderton, B.H.; Betts, J.; Blackstock, W.P.; Brion, J.P.; Chapman, S.; Connell, J.; Dayanandan, R.; Gallo, J.M.; Gibb, G.; Hanger, D.P.; Hutton, M.; Kardalinou, E.; Leroy, K.; Lovestone, S.; Mack, T.; Reynolds, C.H.; Van Slegtenhorst, M. Sites of phosphorylationin tau and factors affecting their regulation. Biochem. Soc. Symp., 2001, (67), 73-80.
131. Woodgett, J.R. Molecular cloning and expression of glycogensynthase kinase-3/factor A. EMBO J., 1990, 9(8), 2431-2438.
132. Tsai, L.H.; Takahashi, T.; Caviness, V.S., Jr.; Harlow, E. Activityand expression pattern of cyclin-dependent kinase 5 in theembryonic mouse nervous system. Development, 1993, 119(4), 1029-1040.
133. Augustinack, J.C.; Sanders, J.L.; Tsai, L.H.; Hyman, B.T. Colocalization and fluorescence resonance energy transfer betweencdk5 and AT8 suggests a close association in pre-neurofibrillarytangles and neurofibrillary tangles. J. Neuropathol. Exp. Neurol., 2002, 61(6), 557-564.
134. Imahori, K.; Uchida, T. Physiology and pathology of tau proteinkinases in relation to Alzheimer's disease. J. Biochem., 1997, 121(2), 179-188.
135. Pei, J.J.; Grundke-Iqbal, I.; Iqbal, K.; Bogdanovic, N.; Winblad, B.; Cowburn, R.F. Accumulation of cyclin-dependent kinase 5 (cdk5)in neurons with early stages of Alzheimer's disease neurofibrillarydegeneration. Brain Res., 1998, 797(2), 267-277.
136. Yamaguchi, H.; Ishiguro, K.; Uchida, T.; Takashima, A.; Lemere, C.A.; Imahori, K. Preferential labeling of Alzheimer neurofibrillarytangles with antisera for tau protein kinase (TPK) I/glycogensynthase kinase-3 beta and cyclin-dependent kinase 5, a componentof TPK II. Acta Neuropathol., 1996, 92(3), 232-241.
137. Leroy, K.; Yilmaz, Z.; Brion, J.P. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilicgrains and in neurones at different stages of neurofibrillarydegeneration. Neuropathol. Appl. Neurobiol., 2007, 33(1), 43-55.
138. Liu, F.; Su, Y.; Li, B.; Zhou, Y.; Ryder, J.; Gonzalez-DeWhitt, P.; May, P.C.; Ni, B. Regulation of amyloid precursor protein (APP)phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBSLett., 2003, 547(1-3), 193-196.
139. Ryder, J.; Su, Y.; Liu, F.; Li, B.; Zhou, Y.; Ni, B. Divergent rolesof GSK3 and CDK5 in APP processing. Biochem. Biophys. Res.Commun., 2003, 312(4), 922-929.
140. Su, Y.; Ryder, J.; Li, B.; Wu, X.; Fox, N.; Solenberg, P.; Brune, K.; Paul, S.; Zhou, Y.; Liu, F.; Ni, B. Lithium, a common drug forbipolar disorder treatment, regulates amyloid-beta precursor proteinprocessing. Biochemistry, 2004, 43(22), 6899-6908.
141. Noble, W.; Olm, V.; Takata, K.; Casey, E.; Mary, O.; Meyerson, J.; Gaynor, K.; LaFrancois, J.; Wang, L.; Kondo, T.; Davies, P.; Burns, M.; Veeranna; Nixon, R.; Dickson, D.; Matsuoka, Y.; Ahlijanian, M.; Lau, L.F.; Duff, K. Cdk5 is a key factor in tauaggregation and tangle formation in vivo. Neuron, 2003, 38(4), 555-565.
142. Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; Wang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.; Krishnamurthy, P.; Wen, Y.; Bhat, R.; Lewis, J.; Dickson, D.; Duff, K. Inhibition of glycogen synthase kinase-3 by lithiumcorrelates with reduced tauopathy and degeneration in vivo. Proc.Natl. Acad. Sci. USA, 2005, 102(19), 6990-6995.
143. Hernandez, F.; Borrell, J.; Guaza, C.; Avila, J.; Lucas, J.J. Spatiallearning deficit in transgenic mice that conditionally over-expressGSK-3beta in the brain but do not form tau filaments. J.Neurochem., 2002, 83(6), 1529-1533.
144. Lucas, J.J.; Hernandez, F.; Gomez-Ramos, P.; Moran, M.A.; Hen, R.; Avila, J. Decreased nuclear beta-catenin, tau hyperphosphorylationand neurodegeneration in GSK-3beta conditional transgenicmice. EMBO J., 2001, 20(1-2), 27-39.
145. Cruz, J.C.; Tseng, H.C.; Goldman, J.A.; Shih, H.; Tsai, L.H.Aberrant Cdk5 activation by p25 triggers pathological eventsleading to neurodegeneration and neurofibrillary tangles. Neuron, 2003, 40(3), 471-483.
146. Vandenheede, J.R.; Yang, S.D.; Goris, J.; Merlevede, W. ATP xMg-dependent protein phosphatase from rabbit skeletal muscle. II.Purification of the activating factor and its characterization as abifunctional protein also displaying synthase kinase activity. J.Biol. Chem., 1980, 255(24), 11768-11774.
147. Welsh, G.I.; Proud, C.G. Glycogen synthase kinase-3 is rapidlyinactivated in response to insulin and phosphorylates eukaryoticinitiation factor eIF-2B. Biochem. J., 1993, 294(Pt 3), 625-629.
148. Park, D.S.; Levine, B.; Ferrari, G.; Greene, L.A. Cyclin dependentkinase inhibitors and dominant negative cyclin dependent kinase 4and 6 promote survival of NGF-deprived sympathetic neurons. J.Neurosci., 1997, 17(23), 8975-8983.
149. Ohshima, T.; Ward, J.M.; Huh, C.G.; Longenecker, G.; Veeranna; Pant, H.C.; Brady, R.O.; Martin, L.J.; Kulkarni, A.B. Targeteddisruption of the cyclin-dependent kinase 5 gene results inabnormal corticogenesis, neuronal pathology and perinatal death.Proc. Natl. Acad. Sci. USA, 1996, 93(20), 11173-11178.
150. Klein, P.S.; Melton, D.A. A molecular mechanism for the effect oflithium on development. Proc. Natl. Acad. Sci. USA, 1996, 93(16), 8455-8459.
151. Liu, S.J.; Zhang, A.H.; Li, H.L.; Wang, Q.; Deng, H.M.; Netzer, W.J.; Xu, H.; Wang, J.Z. Overactivation of glycogen synthasekinase-3 by inhibition of phosphoinositol-3 kinase and proteinkinase C leads to hyperphosphorylation of tau and impairment ofspatial memory. J. Neurochem., 2003, 87(6), 1333-1344.
152. Perez, M.; Hernandez, F.; Lim, F.; Diaz-Nido, J.; Avila, J. Chroniclithium treatment decreases mutant tau protein aggregation in atransgenic mouse model. J. Alzheimer Dis., 2003, 5(4), 301-308.
153. Engel, T.; Goni-Oliver, P.; Lucas, J.J.; Avila, J.; Hernandez, F. Chronic lithium administration to FTDP-17 tau and GSK-3betaoverexpressing mice prevents tau hyperphosphorylation andneurofibrillary tangle formation, but pre-formed neurofibrillarytangles do not revert. J. Neurochem., 2006, 99(6), 1445-1455.
154. Caccamo, A.; Oddo, S.; Tran, L.X.; LaFerla, F.M. Lithium reducestau phosphorylation but not A beta or working memory deficits in atransgenic model with both plaques and tangles. Am. J. Pathol., 2007, 170(5), 1669-1675.
155. Selenica, M.L.; Jensen, H.S.; Larsen, A.K.; Pedersen, M.L.; Helboe, L.; Leist, M.; Lotharius, J. Efficacy of small-moleculeglycogen synthase kinase-3 inhibitors in the postnatal rat model oftau hyperphosphorylation. Br. J. Pharmacol., 2007, 152(6), 959-979.
156. Luna-Medina, R.; Cortes-Canteli, M.; Sanchez-Galiano, S.; Morales-Garcia, J.A.; Martinez, A.; Santos, A.; Perez-Castillo, A. NP031112, a thiadiazolidinone compound, prevents inflammationand neurodegeneration under excitotoxic conditions: potentialtherapeutic role in brain disorders. J. Neurosci., 2007, 27(21), 5766-5776.
157. Serenó, L.; Coma, M.; Rodríguez, M.; Sánchez-Ferrer, P.; Sánchez, M.B.; Gich, I.; Agulló, J.M.; Pérez, M.; Avila, J.; Guardia-Laguarta, C.; Clarimón, J.; Lleó, A.; Gómez-Isla, T. A novel GSK-3 [beta] inhibitor reduces Alzheimer's pathology and rescuesneuronal loss in vivo. Neurobiol. Dis., 2009, 35(3), 359-367.
158. Qing, H.; He, G.; Ly, P.T.; Fox, C.J.; Staufenbiel, M.; Cai, F.; Zhang, Z.; Wei, S.; Sun, X.; Chen, C.H.; Zhou, W.; Wang, K.; Song, W. Valproic acid inhibits Abeta production, neuritic plaqueformation, and behavioral deficits in Alzheimer's disease mousemodels. J. Exp. Med., 2008, 205(12), 2781-2789.
159. Le Corre, S.; Klafki, H.W.; Plesnila, N.; Hubinger, G.; Obermeier, A.; Sahagun, H.; Monse, B.; Seneci, P.; Lewis, J.; Eriksen, J.; Zehr, C.; Yue, M.; McGowan, E.; Dickson, D.W.; Hutton, M.; Roder, H.M. An inhibitor of tau hyperphosphorylation prevents severemotor impairments in tau transgenic mice. Proc. Natl. Acad. Sci.USA, 2006, 103(25), 9673-9678.
160. Fischer, P.M. Turning down tau phosphorylation. Nat. Chem. Biol., 2008, 4(8), 448-449.
161. Lefebvre, T.; Ferreira, S.; Dupont-Wallois, L.; Bussiere, T.; Dupire, M.J.; Delacourte, A.; Michalski, J.C.; Caillet-Boudin, M.L. Evidence of a balance between phosphorylation and O-GlcNAcglycosylation of Tau proteins--a role in nuclear localization. Biochim. Biophys. Acta, 2003, 1619(2), 167-176.
162. Yuzwa, S.A.; Macauley, M.S.; Heinonen, J.E.; Shan, X.; Dennis, R.J.; He, Y.; Whitworth, G.E.; Stubbs, K.A.; McEachern, E.J.; Davies, G.J.; Vocadlo, D.J. A potent mechanism-inspired OGlcNAcaseinhibitor that blocks phosphorylation of tau in vivo.Nat. Chem. Biol., 2008, 4(8), 483-490.
163. Liu, F.; Iqbal, K.; Grundke-Iqbal, I.; Hart, G.W.; Gong, C.X. OGlcNAcylationregulates phosphorylation of tau: a mechanisminvolved in Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101(29), 10804-10809.
164. Jagust, W.J.; Seab, J.P.; Huesman, R.H.; Valk, P.E.; Mathis, C.A.; Reed, B.R.; Coxson, P.G.; Budinger, T.F. Diminished glucosetransport in Alzheimer's disease: dynamic PET studies. J. Cereb.Blood Flow Metab., 1991, 11(2), 323-330.
165. Hoyer, S. Glucose metabolism and insulin receptor signaltransduction in Alzheimer disease. Eur. J. Pharmacol., 2004, 490(1-3), 115-125.
166. Hasegawa, M.; Crowther, R.A.; Jakes, R.; Goedert, M. Alzheimerlikechanges in microtubule-associated protein Tau induced bysulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend onthe degree of sulfation. J. Biol. Chem., 1997, 272(52), 33118-33124.
167. Wilson, D.M.; Binder, L.I. Free fatty acids stimulate thepolymerization of tau and amyloid beta peptides. In vitro evidencefor a common effector of pathogenesis in Alzheimer's disease. Am.J. Pathol., 1997, 150(6), 2181-2195.
168. Friedhoff, P.; Schneider, A.; Mandelkow, E.M.; Mandelkow, E.Rapid assembly of Alzheimer-like paired helical filaments frommicrotubule-associated protein tau monitored by fluorescence insolution. Biochemistry, 1998, 37(28), 10223-10230.
169. Krebs, M.R.; Bromley, E.H.; Donald, A.M. The binding ofthioflavin-T to amyloid fibrils: localisation and implications. J.Struct. Biol., 2005, 149(1), 30-37.
170. Li, W.; Lee, V.M. Characterization of two VQIXXK motifs for taufibrillization in vitro. Biochemistry, 2006, 45(51), 15692-15701.
171. Wischik, C.M.; Edwards, P.C.; Lai, R.Y.; Roth, M.; Harrington, C.R. Selective inhibition of Alzheimer disease-like tau aggregationby phenothiazines. Proc. Natl. Acad. Sci. USA, 1996, 93(20), 11213-11218.
172. Chirita, C.; Necula, M.; Kuret, J. Ligand-dependent inhibition andreversal of tau filament formation. Biochemistry, 2004, 43(10), 2879-2887.
173. Necula, M.; Chirita, C.N.; Kuret, J. Cyanine dye N744 inhibits taufibrillization by blocking filament extension: implications for thetreatment of tauopathic neurodegenerative diseases. Biochemistry, 2005, 44(30), 10227-10237.
174. Congdon, E.E.; Necula, M.; Blackstone, R.D.; Kuret, J. Potency ofa tau fibrillization inhibitor is influenced by its aggregation state.Arch. Biochem. Biophys., 2007, 465(1), 127-135.
175. Taniguchi, S.; Suzuki, N.; Masuda, M.; Hisanaga, S.; Iwatsubo, T.; Goedert, M.; Hasegawa, M. Inhibition of heparin-induced taufilament formation by phenothiazines, polyphenols, andporphyrins. J. Biol. Chem., 2005, 280(9), 7614-7623.
176. Pickhardt, M.; von Bergen, M.; Gazova, Z.; Hascher, A.; Biernat, J.; Mandelkow, E.M.; Mandelkow, E. Screening for inhibitors oftau polymerization. Curr. Alzheimer Res., 2005, 2(2), 219-226.
177. Larbig, G.; Pickhardt, M.; Lloyd, D.G.; Schmidt, B.; Mandelkow, E. Screening for inhibitors of tau protein aggregation intoAlzheimer paired helical filaments: a ligand based approach resultsin successful scaffold hopping. Curr. Alzheimer Res., 2007, 4(3), 315-323.
178. Pickhardt, M.; Larbig, G.; Khlistunova, I.; Coksezen, A.; Meyer, B.; Mandelkow, E.M.; Schmidt, B.; Mandelkow, E.Phenylthiazolyl-hydrazide and its derivatives are potent inhibitorsof tau aggregation and toxicity in vitro and in cells. Biochemistry, 2007, 46(35), 10016-10023.
179. Crowe, A.; Ballatore, C.; Hyde, E.; Trojanowski, J.Q.; Lee, V.M.High throughput screening for small molecule inhibitors ofheparin-induced tau fibril formation. Biochem. Biophys. Res.Commun., 2007, 358(1), 1-6.
180. Crowe, A.; Huang, W.; Ballatore, C.; Johnson, R.L.; Hogan, A.M.; Huang, R.; Wichterman, J.; McCoy, J.; Huryn, D.; Auld, D.S.; Smith, A.B., 3rd; Inglese, J.; Trojanowski, J.Q.; Austin, C.P.; Brunden, K.R.; Lee, V.M. Identification of aminothienopyridazineinhibitors of tau assembly by quantitative high-throughputscreening. Biochemistry, 2009, 48(32), 7732-7745.
181. Lipinski, C.A. Drug-like properties and the causes of poorsolubility and poor permeability. J. Pharmacol. Toxicol. Methods, 2000, 44(1), 235-249.
182. Hattori, M.; Sugino, E.; Minoura, K.; In, Y.; Sumida, M.; Taniguchi, T.; Tomoo, K.; Ishida, T. Different inhibitory responseof cyanidin and methylene blue for filament formation of taumicrotubule-binding domain. Biochem. Biophys. Res. Commun., 2008, 374(1), 158-163.
183. Ciechanover, A. The ubiquitin-proteasome proteolytic pathway.Cell, 1994, 79(1), 13-21.
184. David, D.C.; Layfield, R.; Serpell, L.; Narain, Y.; Goedert, M.; Spillantini, M.G. Proteasomal degradation of tau protein. J.Neurochem., 2002, 83(1), 176-185.
185. Zhang, J.Y.; Liu, S.J.; Li, H.L.; Wang, J.Z. Microtubule-associatedprotein tau is a substrate of ATP/Mg(2+)-dependent proteasomeprotease system. J. Neural Transm., 2005, 112(4), 547-555.
186. Panaretou, B.; Prodromou, C.; Roe, S.M.; O'Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. ATP binding and hydrolysis areessential to the function of the Hsp90 molecular chaperone in vivo.EMBO J., 1998, 17(16), 4829-4836.
187. Ciechanover, A.; Brundin, P. The ubiquitin proteasome system inneurodegenerative diseases: sometimes the chicken, sometimes theegg. Neuron, 2003, 40(2), 427-446.
188. Dickey, C.A.; Dunmore, J.; Lu, B.; Wang, J.W.; Lee, W.C.; Kamal, A.; Burrows, F.; Eckman, C.; Hutton, M.; Petrucelli, L. HSPinduction mediates selective clearance of tau phosphorylated atproline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEBJ., 2006, 20(6), 753-755.
189. Dickey, C.A.; Kamal, A.; Lundgren, K.; Klosak, N.; Bailey, R.M.; Dunmore, J.; Ash, P.; Shoraka, S.; Zlatkovic, J.; Eckman, C.B.; Patterson, C.; Dickson, D.W.; Nahman, N.S., Jr.; Hutton, M.; Burrows, F.; Petrucelli, L. The high-affinity HSP90-CHIP complexrecognizes and selectively degrades phosphorylated tau clientproteins. J. Clin. Invest., 2007, 117(3), 648-658.
190. Dickey, C.A.; Yue, M.; Lin, W.L.; Dickson, D.W.; Dunmore, J.H.; Lee, W.C.; Zehr, C.; West, G.; Cao, S.; Clark, A.M.; Caldwell, G.A.; Caldwell, K.A.; Eckman, C.; Patterson, C.; Hutton, M.; Petrucelli, L. Deletion of the ubiquitin ligase CHIP leads to theaccumulation, but not the aggregation, of both endogenousphospho and caspase-3-cleaved tau species. J. Neurosci., 2006, 26(26), 6985-6996.
191. Shimura, H.; Schwartz, D.; Gygi, S.P.; Kosik, K.S. CHIP-Hsc70complex ubiquitinates phosphorylated tau and enhances cellsurvival. J. Biol. Chem., 2004, 279(6), 4869-4876.
192. Luo, W.; Dou, F.; Rodina, A.; Chip, S.; Kim, J.; Zhao, Q.; Moulick, K.; Aguirre, J.; Wu, N.; Greengard, P.; Chiosis, G. Rolesof heat-shock protein 90 in maintaining and facilitating theneurodegenerative phenotype in tauopathies. Proc. Natl. Acad. Sci.USA, 2007, 104(22), 9511-9516.
193. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M.F.; Fritz, L.C.; Burrows, F.J. A high-affinity conformation of Hsp90confers tumour selectivity on Hsp90 inhibitors. Nature, 2003, 425(6956), 407-410.
194. Levine, B.; Klionsky, D.J. Development by self-digestion:molecular mechanisms and biological functions of autophagy. Dev.Cell, 2004, 6(4), 463-477.
195. Cataldo, A.M.; Hamilton, D.J.; Barnett, J.L.; Paskevich, P.A.; Nixon, R.A. Properties of the endosomal-lysosomal system in thehuman central nervous system: disturbances mark most neurons inpopulations at risk to degenerate in Alzheimer's disease. J.Neurosci., 1996, 16(1), 186-199.
196. Nixon, R.A.; Wegiel, J.; Kumar, A.; Yu, W.H.; Peterhoff, C.; Cataldo, A.; Cuervo, A.M. Extensive involvement of autophagy inAlzheimer disease: an immuno-electron microscopy study. J.Neuropathol. Exp. Neurol., 2005, 64(2), 113-122.
197. Williams, A.; Jahreiss, L.; Sarkar, S.; Saiki, S.; Menzies, F.M.; Ravikumar, B.; Rubinsztein, D.C. Aggregate-prone proteins arecleared from the cytosol by autophagy: therapeutic implications.Curr. Top. Dev. Biol., 2006, 76, 89-101.
198. Hamano, T.; Gendron, T.F.; Causevic, E.; Yen, S.H.; Lin, W.L.; Isidoro, C.; Deture, M.; Ko, L.W. Autophagic-lysosomalperturbation enhances tau aggregation in transfectants with inducedwild-type tau expression. Eur. J. Neurosci., 2008, 27(5), 1119-1130.
199. Wang, Y.; Martinez-Vicente, M.; Kruger, U.; Kaushik, S.; Wong, E.; Mandelkow, E.M.; Cuervo, A.M.; Mandelkow, E. Taufragmentation, aggregation and clearance: the dual role oflysosomal processing. Hum. Mol. Genet., 2009, 18(21), 4153-4170.
200. Zhang, J.Y.; Peng, C.; Shi, H.; Wang, S.; Wang, Q.; Wang, J.Z. Inhibition of autophagy causes tau proteolysis by activating calpainin rat brain. J. Alzheimers Dis., 2009, 16(1), 39-47.
201. Sarkar, S.; Floto, R.A.; Berger, Z.; Imarisio, S.; Cordenier, A.; Pasco, M.; Cook, L.J.; Rubinsztein, D.C. Lithium inducesautophagy by inhibiting inositol monophosphatase. J. Cell Biol., 2005, 170(7), 1101-1111.
202. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P.Immunization with amyloid-[beta] attenuates Alzheimer-diseaselikepathology in the PDAPP mouse. Nature, 1999, 400(6740), 173-177.
203. Masliah, E.; Rockenstein, E.; Adame, A.; Alford, M.; Crews, L.; Hashimoto, M.; Seubert, P.; Lee, M.; Goldstein, J.; Chilcote, T.; Games, D.; Schenk, D. Effects of [alpha]-Synuclein Immunizationin a Mouse Model of Parkinson's Disease. Neuron, 2005, 46(6), 857-868.
204. Sigurdsson, E.M. Tau-focused immunotherapy for Alzheimer'sdisease and related tauopathies. Curr. Alzheimer Res., 2009, 6(5), 446-450.
205. Kumar, N. Taxol-induced polymerization of purified tubulin.Mechanism of action. J. Biol. Chem., 1981, 256(20), 10435-10441.
206. Rowinsky, M.; Eric K. The development and clinical utility of thetaxane class of antimicrotubule chemotherapy agents. Ann. Rev.Med., 1997, 48(1), 353-374.
207. Lee, J.J.; Swain, S.M. Peripheral neuropathy induced bymicrotubule-stabilizing agents. J. Clin. Oncol., 2006, 24(10), 1633-1642.
208. Bassan, M.; Zamostiano, R.; Davidson, A.; Pinhasov, A.; Giladi, E.; Perl, O.; Bassan, H.; Blat, C.; Gibney, G.; Glazner, G.; Brenneman, D.E.; Gozes, I. Complete sequence of a novel proteincontaining a femtomolar-activity-dependent neuroprotectivepeptide. J. Neurochem., 1999, 72(3), 1283-1293.
209. Divinski, I.; Holtser-Cochav, M.; Vulih-Schultzman, I.; Steingart, R.A.; Gozes, I. Peptide neuroprotection through specific interactionwith brain tubulin. J. Neurochem., 2006, 98(3), 973-984.
210. Divinski, I.; Mittelman, L.; Gozes, I. A femtomolar actingoctapeptide interacts with tubulin and protects astrocytes againstzinc intoxication. J. Biol. Chem., 2004, 279(27), 28531-28538.
211. Vulih-Shultzman, I.; Pinhasov, A.; Mandel, S.; Grigoriadis, N.; Touloumi, O.; Pittel, Z.; Gozes, I. Activity-dependent neuroprotectiveprotein snippet NAP reduces tau hyperphosphorylation and enhanceslearning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther., 2007, 323(2), 438-449.
212. Gozes, I.; Stewart, A.; Morimoto, B.; Fox, A.; Sutherland, K.; Schmeche, D. Addressing Alzheimer's Disease Tangles: From NAPto AL-108. Curr. Alzheimer Res., 2009, 6(5), 455-460.
213. Spillantini, M.G.; Goedert, M.; Crowther, R.A.; Murrell, J.R.; Farlow, M.R.; Ghetti, B. Familial multiple system tauopathy withpresenile dementia: A disease with abundant neuronal and glial taufilaments. Proc. Natl. Acad. Sci. USA, 1997, 94 (8), 4113-4118.
214. Heutink, P. Untangling tau-related dementia. Hum. Mol. Genet., 2000, 9(6), 979-986.
215. Kalbfuss, B.; Mabon, S.A.; Misteli, T. Correction of alternativesplicing of tau in frontotemporal dementia and parkinsonism linkedto chromosome 17. J. Biol. Chem., 2001, 276(46), 42986-42993.
216. Puttaraju, M.; Jamison, S.F.; Mansfield, S.G.; Garcia-Blanco, M.A.; Mitchell, L.G. Spliceosome-mediated RNA trans-splicing asa tool for gene therapy. Nat. Biotechnol., 1999, 17(3), 246-252.
217. Rodriguez-Martin, T.; Anthony, K.; Garcia-Blanco, M.A.; Mansfield, S.G.; Anderton, B.H.; Gallo, J.M. Correction of tau missplicingcaused by FTDP-17 MAPT mutations by spliceosomemediatedRNA trans-splicing. Hum. Mol. Genet., 2009, 18(17), 3266-3273.
218. Rodriguez-Martin, T.; Garcia-Blanco, M.A.; Mansfield, S.G.; Grover, A.C.; Hutton, M.; Yu, Q.; Zhou, J.; Anderton, B.H.; Gallo, J.M. Reprogramming of tau alternative splicing by spliceosomemediatedRNA trans-splicing: implications for tauopathies. Proc.Natl. Acad. Sci. USA, 2005, 102(43), 15659-15664.
219. Andorfer, C.; Kress, Y.; Espinoza, M.; de Silva, R.; Tucker, K.L.; Barde, Y.A.; Duff, K.; Davies, P. Hyperphosphorylation andaggregation of tau in mice expressing normal human tau isoforms.J. Neurochem., 2003, 86(3), 582-590.
220. Havens, W.W., 2nd; Cole, J. Successful treatment of dementia withlithium. J. Clin. Psychopharmacol., 1982, 2(1), 71-72.
221. Terao, T.; Nakano, H.; Inoue, Y.; Okamoto, T.; Nakamura, J.; Iwata, N. Lithium and dementia: a preliminary study. Prog.Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(6), 1125-1128.
222. Hampel, H.; Ewers, M.; Burger, K.; Annas, P.; Mortberg, A.; Bogstedt, A.; Frolich, L.; Schroder, J.; Schonknecht, P.; Riepe, M.W.; Kraft, I.; Gasser, T.; Leyhe, T.; Moller, H.J.; Kurz, A.; Basun, H. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J.Clin. Psychiatry, 2009, 70(6), 922-931.
223. Tariot, P.N.; Aisen, P.S. Can lithium or valproate untie tangles inAlzheimer's disease? J. Clin. Psychiatry, 2009, 70(6), 919-921.
224. Tariot, P.N.; Raman, R.; Jakimovich, L.; Schneider, L.; Porsteinsson, A.; Thomas, R.; Mintzer, J.; Brenner, R.; Schafer, K.; Thal, L. Divalproex sodium in nursing home residents withpossible or probable Alzheimer Disease complicated by agitation: arandomized, controlled trial. Am. J. Geriatr. Psychiatry, 2005, 13(11), 942-949.
225. Martinez, A.; Perez, D.I. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J. Alzheimers Dis., 2008, 15(2), 181-191.